Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide association studies of placebo and duloxetine response in major depressive disorder.

The pharmacogenomics journal - 22 May 2018

Maciukiewicz M, Marshe V S, Tiwari A K, Fonseka T M, Freeman N, Kennedy J L, Rotzinger S, Foster J A, Kennedy S H, Müller D J

Abstract excerpt

We investigated variants associated with treatment response in depressed patients treated with either the antidepressant duloxetine or placebo using a genome-wide approach. Our sample (N=391) included individuals aged 18-75 years, diagnosed with major depressive disorder and treated with either duloxetine or placebo for up to 8 weeks. We conducted genome-wide associations for treatment response as operationalized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to CD56 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to DNA-Binding Proteins

Share to Double-Blind Method

Share to Nerve Tissue Proteins

Share to Placebos

Share to Transcription Factors

Source

Identifiers

PMID: 28696415
DOI: 10.1038/tpj.2017.29

Genes

NCAM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association studies of placebo and duloxetine response in major depressive disorder.PMID 28696415Read ↗

GWAS-based machine learning approach to predict duloxetine response in major depressive disorder.Semantic proximity Read ↗

Genomic predictors of response to antidepressants in Major depressive disorder (MDD): A GWAS-Based Study on Indian cohortSemantic proximity Read ↗

Genome-wide meta-analyses of non-response to antidepressants provide insights into underlying molecular genetics and suggest potential pharmacotherapies.Semantic proximity Read ↗

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.Semantic proximity Read ↗

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.Semantic proximity Read ↗

Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.Semantic proximity Read ↗

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Semantic proximity Read ↗

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.Semantic proximity Read ↗

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.Semantic proximity Read ↗

Genome-wide association studies of antidepressant outcome: a brief review.Semantic proximity Read ↗

A genomewide association study of citalopram response in major depressive disorder.Semantic proximity Read ↗

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.